v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities    
Net loss $ (19,864,902) $ (29,918,802)
Adjustments to reconcile net loss to net cash used in operating activities    
Change in fair value of warrant liabilities (89,010) (717,645)
Stock-based compensation expense 2,227,859 1,630,341
Changes in operating assets and liabilities:    
Prepaid clinical trial costs (current and non-current) 540,601 (1,282,027)
Prepaid expenses and other current assets 1,750 (411,798)
Accounts payable (3,407,773) 2,291,186
Accrued expenses and other current liabilities (4,003,168) (5,135,171)
Net cash used in operating activities (24,594,643) (33,543,916)
Cash flows from financing activities    
Proceeds from issuance of short-term debt 406,875 976,904
Repayment of short-term debt (458,154) (518,750)
Proceeds from issuance of common stock, common stock warrants, prefunded warrants and from modification of existing warrants, in offerings, net of transaction costs 17,154,911 23,194,488
Net cash provided by financing activities 25,557,104 23,652,791
Net decrease in cash and cash equivalents 962,461 (9,891,125)
Cash and cash equivalents, beginning of period 13,476,331 23,367,456
Cash and cash equivalents, end of period 14,438,792 13,476,331
Supplemental disclosures of cash flow information:    
Cash paid for taxes 3,369 3,417
Cash paid for interest 13,402 18,497
Noncash Investing and Financing Activities:    
Settlement of bonuses in form of stock options 0 330,816
Warrant modification recorded in stockholders' equity 0 1,073,416
Transaction costs related to offerings included in accounts payable and accrued expenses 136,267 143,136
Common Stock Warrants [Member]    
Cash flows from financing activities    
Proceeds from exercise of common stock warrants 6,976,065 149
Noncash Investing and Financing Activities:    
Issuance of warrants 9,766,116 10,421,225
Prefunded Warrants [Member]    
Noncash Investing and Financing Activities:    
Issuance of warrants 0 470,057
Underwriter Warrants [Member]    
Noncash Investing and Financing Activities:    
Issuance of warrants 0 165,952
The Market Offering Agreement "ATM Agreement" [Member]    
Cash flows from financing activities    
Proceeds from issuance of common stock in ATM offering, net of transaction costs $ 1,477,407 $ 0